BACKGROUND: Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics. OBJECTIVE: What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)? METHODS: We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication. CONCLUSION: The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.
No takes yet. Share an insight, caveat, or question.
O'Dwyer et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: